|
Market Closed -
Nasdaq
16:00:00 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 1.600 USD | -0.62% |
|
-10.61% | -78.26% |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
| Market Cap | 36.29M 31.45M 29.68M 26.92M 50.5M 3.48B 50.87M 354M 137M 1.76B 136M 133M 5.61B | P/E 2026 * |
-0.34x | P/E 2027 * | -0.67x |
|---|---|---|---|---|---|
| Enterprise Value | 36.29M 31.45M 29.68M 26.92M 50.5M 3.48B 50.87M 354M 137M 1.76B 136M 133M 5.61B | EV / Sales 2026 * |
0.27x | EV / Sales 2027 * | 0.21x |
| Free-Float |
95.33% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| KPTI | Delayed | |
CBOE
| KPTI | Real-time | |
|
Tradegate
| 25K0 | Real-time | |
|
Boerse Muenchen
| 25K0 | Real-time | |
|
Deutsche Boerse AG
| 25K0 | Delayed | |
|
Börse Stuttgart
| 25K0 | Delayed |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 day | -0.62% | ||
| 1 week | -10.61% | ||
| Current month | -22.33% | ||
| 1 month | -20.79% | ||
| 3 months | -83.16% | ||
| 6 months | -79.62% | ||
| Current year | -78.26% |
| 1 week | 1.24 |  | 1.75 |
| 1 month | 1.24 | | 2.14 |
| Current year | 1.24 | | 10.99 |
| 1 year | 1.24 | | 10.99 |
| 3 years | 1.24 | | 29.25 |
| 5 years | 1.24 | | 220.95 |
| 10 years | 1.24 | | 444.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 2021-05-02 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 2025-01-02 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 62 | 2012-12-31 |
| Director/Board Member | 61 | 2013-03-31 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 2013-10-02 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/1/26 | Sell | Controller/Auditor | -19 | 0.0001% | ||
| 7/28/26 | Sell | Executive/Senior Manager | -189 | 0.0008% | ||
| 5/21/26 | Free | Director | 15,508 | 0.0688% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | -10.61% | -75.19% | -91.79% | 36.52M | |
| +1.57% | -4.11% | +41.74% | -4.64% | 78.04B | |
| +1.89% | +0.78% | +523.95% | +30.03% | 57.48B | |
| +0.16% | -1.72% | -15.98% | -35.81% | 57.4B | |
| +0.35% | -3.14% | -11.03% | +26.34% | 48.81B | |
| +2.38% | +0.10% | +1.49% | +155.34% | 45.5B | |
| +0.10% | -1.57% | +50.05% | -15.20% | 32.08B | |
| +0.59% | -3.60% | +47.04% | +92.49% | 24.62B | |
| -0.62% | -3.79% | +0.84% | +145.92% | 20.77B | |
| +2.24% | -0.40% | +66.12% | +100.09% | 15.75B | |
| Average | +0.62% | -3.69% | +62.90% | +40.28% | 38.05B | |
| Weighted average by Cap. | +0.78% | -2.52% | +94.11% | +36.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 136M 118M 111M 101M 189M 13B 190M 1.32B 510M 6.59B 509M 498M 20.96B | 174M 150M 142M 129M 242M 16.64B 243M 1.7B 653M 8.44B 652M 638M 26.83B |
| Net income | -160M -139M -131M -119M -223M -15.35B -225M -1.56B -603M -7.79B -602M -588M -24.76B | -115M -99.56M -93.95M -85.23M -160M -11.01B -161M -1.12B -432M -5.59B -432M -422M -17.76B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-14 | US$1.600 | -0.62% | 991,586 |
| 26-09-11 | US$1.610 | -0.62% | 6,737,667 |
| 26-09-10 | US$1.620 | -4.14% | 800,950 |
| 26-09-09 | US$1.690 | -1.74% | 772,567 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KPTI Stock
Select your edition
All financial news and data tailored to specific country editions
